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We investigated the expression of neuronal nitric oxide synthase (nNOS) in a rat retina model of chronic glaucoma, which was pro-
duced by electrocauterization of the episcleral vessels. Western-blot analysis showed that nNOS expression was signiﬁcantly increased in
cauterized retinas. nNOS immunoreactivity was observed in the cells of both the inner nuclear layer and the ganglion cell layer. Double
labeling of retinal ganglion cells (RGCs) revealed that RGCs in the retina of cauterized rat was nNOS-immunopositive. Systemic admin-
istration of L-NAME (NG-nitro-L-arginine-methyl-ester), a non-speciﬁc NOS inhibitor, reduced RGC loss in cauterized rat retina, but
there was no statistical signiﬁcance (P = .06). These results suggest that the cytotoxicity of excessive NO plays a role in selective
RGC loss in glaucoma.
 2007 Elsevier Ltd. All rights reserved.
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Glaucoma is a major cause of irreversible blindness
worldwide. In glaucoma, the most distinctive pathologic
change is the selective loss of retinal ganglion cells (RGCs)
(Morgan, 2002) via a mechanism involving the apoptosis
pathway (Quigley et al., 1995). The mechanism of RGC
loss in glaucoma is not fully understood, but the depletion
of neurotrophic factors by blockage of axoplasmic ﬂow
through direct compression, ischemia, and inﬂammatory
processes, glutamate excitotoxicity, and reactive oxygen,
have been proposed as possible mechanisms (Ko, Hu,
Ritch, & Sharma, 2000; Quigley et al., 2000).
Nitric oxide (NO), a free radical with a half-life of a few
seconds, plays various physiological and pathological roles
in the nervous system (Dawson, Dawson, & Snyder, 1994;
Dawson & Snyder, 1994). NO is synthesized from its pre-
cursor, L-arginine, by the enzyme NO synthase (NOS) (Pal-0042-6989/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
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NOS have been identiﬁed: neuronal (nNOS), endothelial
(eNOS), and inducible (iNOS) (Dawson & Snyder, 1994).
The neuronal and endothelial NOS isoforms are constitu-
tively expressed and are calcium- and calmodulin-depen-
dent, whereas iNOS is calcium-independent and is
induced by endotoxin and cytokines (Kuo & Schroeder,
1995; Moncada, Palmer, & Higgs, 1991; Nathan & Xie,
1994).
NO has been implicated as a neurotoxin that plays a role
in various neurodegenerative diseases of the central ner-
vous system. Animal models of human neurodegenerative
diseases have implicated NO in stroke (Malinski, Bailey,
Zhang, & Chopp, 1993), multiple sclerosis (Bo et al.,
1994), and Parkinson’s disease (Hunot et al., 1996). In
the glaucomatous optic nerve head, excessive NO may be
responsible, at least in part, for degeneration of axons of
retinal ganglion cells. Induction and up-regulation of iNOS
has been found in astrocytes in the prelaminar and lamina
cribrosa of optic nerve heads of glaucoma patients (Liu &
Neufeld, 2000; Neufeld, Hernandez, & Gonzalez, 1997),
and inhibition of NOS delays axonal degeneration and
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Ball, 1999). The pharmacologic use of aminoguanidine,
an iNOS inhibitor, signiﬁcantly inhibits the loss of RGCs
in an experimental rat model of chronic ocular hyperten-
sion (Neufeld, 2004; Neufeld, Sawada, & Becker, 1999).
Although most studies of the role of NOS in glaucoma
have focused on iNOS, a change in nNOS expression asso-
ciated with glutamate excitotoxicity may be a mechanism
of RGC loss in glaucoma. In many glutaminergic junc-
tions, NO is the post-junctional, intracellular mediator
for glutamate released into the synapse. Although gluta-
mate neurotoxicity in primary neuronal cell culture is med-
iated, at least in part, by excess NO (Dawson, Dawson,
Bartley, Uhl, & Snyder, 1993; Dawson, Dawson, London,
Bredt, & Snyder, 1991), the role of nNOS in glaucomatous
degeneration is not fully understood. Therefore, in the
present study, we investigated the possible role of NO in
the glaucomatous loss of RGCs by examining retinal
nNOS expression in a rat model of chronic glaucoma. In
particular, we determined the localization of nNOS-immu-
noreactive cells based on the selective loss of RGCs.
2. Materials and methods2.1. Rat glaucoma model
Forty-eight adult male Sprague–Dawley rats weighing 200–250 g were
used in this study. At 1 and 6 weeks after cauterization, six eyes in each
experimental group were used for Western-blot and immunohistochemical
analysis of nNOS expression, and at 4 weeks after cauterization, six eyes in
each group were used for counting RGCs marked by retrograde labeling.
All animals were treated in accordance with the ARVO Statement for Use
of Animals in Ophthalmic and Vision Research. The Animal Care Com-
mittee of the College of Medicine of The Catholic University of Korea
approved the animal protocols and monitored animal use. Animals were
housed with a 14-h light/10-h dark cycle with standard food and water
provided ad libitum.
Elevated intraocular pressure (IOP) was induced in one eye of animals
by cauterizing the three episcleral veins as follows. Rats were anesthetized
with an intraperitoneal (i.p.) injection of 4% chloral hydrate (Merck, NJ,
USA; 400 mg/kg). After conjunctival incision, extraocular muscles were
isolated, and the four major limbal draining veins were identiﬁed based
on location, relative immobility, larger diameter, and branching pattern.
Three of the episcleral veins were cauterized using a cautery (Bovie Com-
pany, FL, USA) and a surgical microscope (Olympus, Tokyo, Japan) as
previously described (Shareef, Garcia-Valenzuela, Salierno, Walsh, &
Sharma, 1995). Normal perfusion of the retina after cauterization was
conﬁrmed by planar ophthalmoscopy. Only those eyes that did not suﬀer
scleral burns with subsequent necrosis or any complications from surgery
were used for subsequent analysis.
IOP was measured using a tonometer (Tono-Pen; Solan, Florida,
USA) after topical anesthesia with 0.5% Alcaine eye drops (Alcon Inc.,
Fort Worth, TX). Nine readings were taken and averaged. Animals were
kept as calm as possible to minimize eﬀects on the IOP readings. The aver-
age IOP was measured in rats at baseline (prior to cauterization) and at 1,
3, 7, 10, 14, 21, 35, and 42 days post-cauterization.
2.2. Retrograde labeling and counting of RGCs
We conducted retrograde RGC labeling by the stereotaxic addition of
two diﬀerent dyes, Fluoro-gold (FG, Fluorochrome, USA) or 4-Di-10-
ASP (DiA, Molecular Probes, Eugene, USA). We found that FG wasthe best dye for identifying RGCs or retrograde axoplasmic ﬂow distur-
bance and for quantitative analysis, but it was inadequate for double
staining of RGCs. DiA stained RGCs well and performed better in double
staining.
Brieﬂy, after ﬁxing the head of anesthetized rats in a stereotaxic appa-
ratus (Stoelting, Wood Dale, IL) with the skull held horizontally, FG and
DiA tracer was applied into the superior colliculus using these coordi-
nates: 6 mm posterior to the rat bregma, 1.2 mm lateral to the midline,
and 3.8–4.2 mm depth from the top of the skull. These tracers are taken
up by the axon terminals of the RGCs in the superior colliculus and trans-
ported in a retrograde manner to the retinal somas. Eyes were enucleated
4–5 days after injection of FG and DiA, and the retinas were ﬁxed in 4%
paraformaldehyde in 0.1 M phosphate buﬀer, pH 7.4 (PB), for 30 min.
Each retina was then isolated as ﬂatted wholemounts by four radial inci-
sions, and mounted on slides with the vitreal side facing up.
Retinal wholemounts were examined and photographed with a ﬂuores-
cence microscope (Axiophot, Zeiss, Oberkochen, Germany). RGC count-
ing was performed as described previously (Levkovitch-Verbin et al.,
2003). Each retinal quadrant was divided into central, middle, and periph-
eral locations (1, 2, and 3 mm from the optic disc, respectively), and then
the number of RGCs in each of the six ﬁelds (one central ﬁeld, two middle
ﬁelds, and three peripheral ﬁelds) of each quadrant were counted. Corre-
sponding regions from each retina of the normal and cauterized groups
were compared. A labeled RGC was counted if the entire cell or the
nucleus of the cell was visible within the micrograph. To minimize vari-
ability, RGC counting was performed in a masked fashion by the same
investigator.2.3. Western-blot analysis
The retinas were homogenized in RIPA buﬀer (0.5 M Tris–HCl, pH
7.5, 1% Triton X-100, 5% SDS, 5% deoxycholic acid, 10% glycerol,
1 mM EDTA, 1 mM phenylmethylsulfonyl ﬂuoride, 5 lg/ml aprotinin,
1 lg/ml leupeptin, 1 lg/ml pepstatin, 200 mM sodium orthovanadate,
200 mM sodium ﬂuoride). Tissue extracts were incubated for 10 min on
ice and then clariﬁed by centrifugation at 10,000g for 25 min at 4 C. Total
protein in the retinal extracts was determined using a standard bicinchon-
inic acid (BCA) assay (Pierce, Rockford, IL).
Retinal extracts (30 lg total protein) were resuspended in 5· sample
buﬀer (60 mM Tris–HCl (pH 7.4), 25% glycerol, 2% SDS, 14.4 mM 2-
mercaptoethanol, and 0.1% bromophenol blue) at a 4:1 ratio, boiled for
5 min, and resolved by SDS–PAGE. The separated proteins were then
transferred to a nitrocellulose membrane (Hybond-C; Amersham Pharma-
cia Biotech, Freiburg, Germany). The membranes were washed and
blocked for 45 min with 5% skimmed milk powder in TBST buﬀer
(20 mM Tris–HCl, pH 7.6, 137 mMNaCl, 0.1% Tween 20). The blots were
then incubated for 15 h at 4 C with antibodies against nNOS (Sigma, CA,
USA), iNOS (Upstate, CA, USA) or eNOS (Transduction Laboratory,
CA, USA) that were diluted 1:1000 in the blocking solution. The mem-
brane was rinsed by three 10 min washes with TBST and then incubated
with horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary
antibody (1:10,000) for 1 h at room temperature. Bound antibodies were
detected using an enhanced chemiluminescence system (ECL; Amersham,
Piscataway, NJ) and X-ray ﬁlm, and the signal intensity was measured
using an ImageMasterVDS system (Pharmacia Biotech, San Francisco,
CA). Immunoblot experiments were performed three times for each retina
and then quantiﬁed as the mean value.2.4. Immunohistochemistry
At the end of each experimental period, eyes were enucleated and dis-
sected, and the posterior eyecups were placed in chilled ﬁxative (4% para-
formaldehyde in PB). Isolated retinas were divided into small pieces and
immersion-ﬁxed in the same ﬁxative for 2 h at 4 C. After several washes,
the ﬁxed retinas were cryoprotected in PB containing 30% sucrose for 6 h
at 4 C and stored at 70 C. Samples for vibratome sectioning were pre-
embedded in 3% agar in deionized water. Vibratome sections (50 lm) were
Fig. 1. Intraocular pressure (IOP) after cauterization. A chronic glaucoma
rat model was prepared as described in Section 2, and the IOPs of control
(d) and cauterized (s) eyes were measured at the indicated times post-
cauterization. The experimental group exhibited a signiﬁcant and
sustained increase in IOP during the experimental period; the IOP was
elevated to 30.5 ± 2.0 mm Hg one day after cauterization, and it remained
at this level throughout the 6-week follow-up period (32.1 ± 0.9 mm Hg,
P < .05). Error bars = SD. *P < .05, compared to the control.
2734 S.H. Park et al. / Vision Research 47 (2007) 2732–2740collected and washed several times in phosphate-buﬀered saline, pH 7.4
(PBS). The sections were incubated in 10% normal donkey serum in
PBS for 1 h at room temperature and then incubated with a rabbit poly-
clonal antibody against nNOS (1:7000; Sigma) in PBS overnight at 4 C.
For nNOS immunohistochemistry, sections were washed the next day
several times with PBS and then incubated in HRP-conjugated donkey
anti-rabbit IgG antibody (1:1000; Jackson Immuno-Research Laborato-
ries, West Grove, PA, USA) for 2 h at room temperature. The sections
were washed several times in 0.05 M Tris–HCl buﬀer, pH 7.4 (TB) for
10 min each, and the immune reaction was visualized by incubation in
TB containing 0.05% 3,3 0-diaminobenzidine tetrahydrochloride (DAB;
Sigma) and 0.01% H2O2 for 1 min. Sections were observed and photo-
graphed with an Olympus light microscope. For quantitative analysis of
the number of nNOS-positive cells, the cell bodies were counted in the
ganglion cell layer (GCL) and inner nuclear layer (INL) under the micro-
scope at the magniﬁcation of 200·. Each ﬁeld was outlined with an ocular
graticule, measuring 0.0144 mm2 (0.48 mm width · 0.03 mm height), (n
= 6 per control and 6 weeks after cauterization, three sections for each
eye). Statistical analysis was performed using Student’s t-test as described
in quantiﬁcation and statistics.
Double labeling for nNOS was performed the next day after several
washes with PBS. Sections were incubated with goat anti-rabbit ﬂuoro-
phore-conjugated secondary antibody (1:200; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), washed, cover-slipped, and examined by confo-
cal laser-scanning microscopy (Bio-Rad Laboratories, Hercules, CA,
USA).
2.5. Inhibition of NOS using L-NAME
NG-Nitro-L-arginine-methyl-ester (L-NAME), a non-speciﬁc NOS
inhibitor, was administered i.p. at 40 mg/kg one day after cauterization.
The L-NAME was dissolved in PBS and injected once daily for 4 weeks
(n = 6). Four weeks after L-NAME administration, the eyes were enucle-
ated and examined for the extent of RGC loss. The control animals
received i.p. injections of the PBS vehicle for 4 weeks.
2.6. Quantiﬁcation and statistical analysis
All data are expressed as means ± SD. Comparisons between two
groups were performed using Student’s t-tests and paired t-tests. Compar-
isons among multiple groups were performed using one-way analysis of
variance (ANOVA) with Duncan’s multiple pair-wise comparison tests.
Diﬀerences were considered signiﬁcant at P < .05.3. Results
3.1. Elevation of intraocular pressure (IOP)
The IOP was 17.75 ± 1.29 mm Hg in normal control
eyes, but in the experimental group (n = 24), it had
increased to 30 mm Hg at one day post-cauterization
(30.5 ± 2.0 mm Hg). The IOP in the experimental group
remained elevated over the entire 6-week experimental per-
iod, with an average of 32.1 ± 0.9 mm Hg (P < .05)
(Fig. 1).3.2. Expression of NOS isoforms
Western-blot analysis was used to quantify levels of
NOS isoforms in normal and cauterized rat retinas. Densi-
tometric analysis revealed that nNOS expression was sig-
niﬁcantly higher in cauterized eyes than in normal eyes,
and that this elevated nNOS expression in cauterized eyeswas sustained throughout the experimental period. The
expression of iNOS was increased signiﬁcantly at 1-week
post-cauterization but did not change thereafter, and no
signiﬁcant changes in eNOS expression were observed
(Fig. 2).
3.3. nNOS immunoreactivity
In the normal retinas, nNOS immunoreactivity was
observed in cells of the ganglion cell layer (GCL) and inner
nuclear cell layer (INL) (Fig. 3a and b). Based on their
morphologies and locations, the immunoreactive cells in
the INL were thought to be amacrine cells (arrowheads)
and bipolar cells (open arrows) (Fig. 3). In cauterized rat
retinas, the distribution of nNOS immunoreactivity 6
weeks after cauterization was the same as that of the nor-
mal retina. However, the intensity of the signal and the
number of immunopositive cells were higher than those
of the normal retina (Fig. 3c and d). In the quantitative
analysis, cells with nNOS immunoreactivity in the GCL
and INL were signiﬁcantly increased, compared with those
of control retinas. The INL was numerically superior to
GCL in the distribution of nNOS immunoreactive cells in
both groups (Table 1).
3.4. Expression of nNOS in the ganglion cell layer
We examined whether the RGCs themselves expressed
nNOS using immunohistochemistry with retrograde label-
ing of RGCs with DiA (Fig. 4a and d). We conﬁrmed that
the INL and GCL exhibited nNOS immunoreactivity in
normal rat retinas (Fig. 4b). The number of nNOS-positive
cells in the GCL increased after cauterization (Fig. 4e). At
Fig. 2. Expression of three NOS isoforms in the retina of the chronic glaucoma model. Proteins were extracted from retinas of control and experimental
rats at 0, 1, and 6 weeks post-cauterization. Expression levels of nNOS, iNOS, and eNOS proteins were determined by immunoblot analysis (a) and the
relative intensity of NOS isoforms from immunoblots was measured by densitometric analysis (b). Error bars = SD. *P < .05, compared to the control; 
P < .05, compared to 1-week post-cauterization.
Fig. 3. nNOS-immunoreactive cells in normal (a and b) and cauterized (c and d) rat retinas. Light micrographs showing nNOS immunoreactivity in the
INL and GCL are shown. Arrowheads indicate amacrine cells, and open arrows indicate cell bodies of bipolar cells in the INL. Arrows in the GCL
indicate displaced amacrine cells or ganglion cells. At 6 weeks post-cauterization, nNOS immunoreactivity increased in both intensity and frequency in the
INL and GCL (d). Scale bar = 30 lm.
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ized in the GCL were identiﬁed as RGCs by their overlap-
ping ﬂuorescence after retrograde labeling of ganglion cells(Fig. 4f, arrows). However, in normal rat retinas, such
overlapping of ﬂuorescence was not observed, indicating
that the nNOS-positive cells in the GCL of non-cauterized
Table 1
The average number of nNOS-positive cell count (per 0.0144 mm2 retinal
area) in the GCL and INL after chronic ocular hypertension injury
Normal Cauterization
GCL 1.1 ± 0.4 3.4 ± 0.9*
INL 3.8 ± 0.9 7.7 ± 0.8*
Values are expressed as means ± SD. Statistical signiﬁcance was evaluated
by Student’s t-test (n = 6 per control and week 6, three sections for each
eye). Cauterization, 6 weeks post-cauterization; GCL, ganglion cell layer;
INL, inner nuclear layer. *P < .05 compared to the control retina.
Fig. 5. Eﬀect of L-NAME on IOP. L-NAME (40 mg/kg) was injected into
the peritoneum of normal and chronic glaucoma model rats every day for
4 weeks, and their IOPs were measured. After cauterization, the average
IOP was higher than that of control eyes, and L-NAME had no eﬀect on
this increase, which was similar to that observed in the non-treatment
group. *P < .05, compared to the control.
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(Fig. 4c).
3.5. Eﬀect of L-NAME on ganglion cell protection in chronic
glaucoma
We next examined the eﬀect of administration of
L-NAME, a non-speciﬁc NOS inhibitor, on the IOP and
on RGC loss after cauterization. In the absence of
L-NAME treatment, cauterization increased the average
IOP from 17 to 32 mm Hg, and L-NAME treatment did
not alter this response. At 4 weeks post-cauterization, both
the L-NAME-treated and non-treated rats had similar IOP
(Fig. 5). We examined the RGC-protective eﬀects of
L-NAME by counting the number of RGCs after retro-
grade transport of FG into the ganglion cells. After 4
weeks of elevated IOP, retinas from L-NAME-treated
and non-treated rats had 107,716 ± 2833 and
101,646 ± 2944 ganglion cells, respectively, statistically less
than in non-cauterized rat retinas (P < .05). L-NAME was
found to inhibit RGC loss in the chronic glaucoma ratFig. 4. Expression of nNOS in the GCL of normal (a–c) and cauterized (d–f)
labeling, and the resulting image was merged with that showing nNOS immun
labeled ganglion cells was detected only in the cauterized rat retina (f, arrows
layer. Scale bar = 50 lm.model. But this inhibition was not statistically signiﬁcant
(P = .0618) when assessed by a two-tailed t-test. (Fig. 6)
4. Discussion
Glaucoma is characterized by progressive cupping of the
optic nerve head, selective loss of RGCs, and loss of visual
ﬁeld. Elevated IOP is considered a primary risk factor for
the initiation and progression of glaucomatous optic
neuropathy.rat retinas. RGCs were labeled with DiA (a and d, green) by retrograde
oreactivity (b and e, red). Expression of nNOS immunoreactivity on DiA-
). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear
Fig. 6. Neuroprotective eﬀect of L-NAME on loss of RGCs in the chronic glaucoma rat model. Chronic glaucoma rats received daily injections with L-
NAME (40 mg/kg). Ganglion cells were labeled with FG by retrograde transport in the L-NAME-treated and non-treated rats (a). At 4 weeks post-
cauterization, the increased IOP reduced the number of RGCs by 35%. This reduction was ameliorated by L-NAME treatment (b), but the statistical
signiﬁcance of the eﬀect was marginal, as assessed by a two-tailed t-test (P = .0618).
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generative disorders. In the neural retina, it plays an impor-
tant role in regulating phototransduction, modulating
output at photoreceptor synapses, and controlling ganglion
cell excitability (Ahmad et al., 1994; Cudeiro & Rivadulla,
1999; Savchenko, Barnes, & Kramer, 1997; Shiells & Falk,
1992). Recently, NO and NOSs have been studied in con-
nection with the loss of RGCs via the apoptosis pathway
in glaucoma, but a direct link between retinal NO activity
and IOP elevation has yet to be established. Most studies of
the role of NOS in glaucoma have focused on iNOS. iNOS-
positive cells are not detected in normal tissue, but are
sparsely present in glaucomatous optic nerve heads. Immu-
nohistochemistry data suggest that these cells are reactive
astrocytes and microglia. Neufeld et al. hypothesized that
the excessive NO produced by astrocytes plays a major
neurodestructive role in the chronic degeneration of axons
in the optic nerve head that is characteristic of glaucoma
(Liu & Neufeld, 2000; Neufeld et al., 1997). However,
nNOS has not been a matter of concern in a glaucomamodels. Recently, increased expression of nNOS in the ret-
ina and optic nerve head was reported in rats with elevated
IOP (Vidal et al., 2006).
We hypothesized that neuronal NO might be a mediator
of RGC death in glaucoma based on several observations:
(i) glaucoma is characterized by selective ganglion cell loss,
(ii) elevated glutamate concentration has been observed in
the vitreous of primary open-angle glaucoma patients, and
(iii) in many glutaminergic junctions, the post-junctional,
intracellular mediator for glutamate is NO produced by
nNOS.
An experimental rat model of chronic glaucoma pro-
duced by the electrocauterization of episcleral vessels (Sha-
reef et al., 1995) is similar to human glaucoma and is
frequently used for glaucoma studies. In this model, a
decrease in the outﬂow of aqueous humor causes sustained
elevation of the IOP, resulting in chronic damage to the
neuroretina. In addition, ischemia is prevented because
the elevated IOP does not exceed systolic blood pressure
and less variation between individuals is observed (Urcola,
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study we used a glaucoma rat model in which three episcle-
ral vessels were cauterized. This treatment resulted in a
consistent, 1.7-fold increase in IOP during the 6 weeks after
cauterization. Pang et al. investigated the involvement of
iNOS, but not nNOS, in experimental glaucoma model
using episcleral injection of hypertonic saline and con-
cluded that glaucomatous optic neuropathy was not associ-
ated with a signiﬁcant change in iNOS expression in the
retina, which was not consistent with the previously pub-
lished results from Neufeld et al. (Neufeld et al., 1999; Pang
et al., 2005). They pointed out technical diﬀerences in the
elevation of IOP to explain the discrepancy and presumed
that cauterization of episcleral vessels might provide local-
ized ocular ischemia and ocular congestion. We cannot
exclude the possibility of choroidal circulation disturbance
in our glaucoma model, but there is not deﬁnite evidence to
support this histologically. Besides, based on choroidal cir-
culation disturbance alone, it is hard to explain the various
changes in inner retina observed in our experiments using
episcleral vein cauterization.
Findings of nNOS activity in the retina have been
reported previously, but the particular cell type involved
has not been clearly identiﬁed. Total NO levels increased
twofold in the retina of an experimental glaucoma model
(Siu et al., 2002). Although nNOS immunoreactivity has
been associated with amacrine cells in the INL, displaced
amacrine cells in the GCL, and sometimes RGCs, the
localization of nNOS immunoreactivity to RGCs has
not been a consistent ﬁnding of published studies. Neufeld
et al. reported localization of nNOS to photoreceptors,
amacrine cells, and RGCs in normal rat and human reti-
nas (Neufeld, Shareef, & Pena, 2000). However, optic
nerve transection induces widespread expression of nNOS
immunoreactivity in rat RGCs that normally do not
express this enzyme activity, suggesting that axotomized
ganglion cells degenerate via NO-mediated excitotoxicity
(Lee et al., 2003).
This study demonstrated a signiﬁcant increase in expres-
sion of nNOS in the retina of a chronic glaucoma model.
Levels of nNOS protein also increased signiﬁcantly over
time. Because the most distinctive pathologic change in
glaucoma is the loss of RGCs, we labeled RGCs using ste-
reotactic surgery to distinguish them from displaced ama-
crine cells and then observed the localization of the
nNOS-immunoreactive cells. Our data demonstrate that
chronically elevated IOP increases the expression of nNOS
immunoreactivity both in RGCs that normally do not
express this enzyme activity and in amacrine cells that nor-
mally express this enzyme activity in some degrees.
Although the mechanism by which chronically increased
IOP induces an increase in nNOS expression in the retina is
unknown, glutamate excitotoxicity may be involved. Glu-
tamate is the principal excitatory neurotransmitter in the
CNS and the retina and has been found to be increased
in glaucoma (Dreyer, Zurakowski, Schumer, Podos, & Lip-
ton, 1996). RGCs damaged by direct compression, ische-mia, and inﬂammatory processes produce excess
glutamate, and the glutamate stimulates RGCs by binding
to their N-methyl-D-aspartic acid (NMDA) receptors. This
interaction leads to a large inﬂux of Ca2+, which causes
inappropriate activation of complex cascades of nucleases,
protease, and lipases, resulting in cell death (Hollmann &
Heinemann, 1994; Yang, 2004). A Ca2+/calmodulin-depen-
dent NOS isozyme is among these activated enzymes.
Pharmacological inhibition of NOS activity has been
investigated for its possible neuroprotective eﬀect in glau-
coma. In a rat glaucoma model, pharmacological use of
aminoguanidine, an inhibitor of NOS-2, signiﬁcantly
reduces the loss of RGCs (Neufeld, 2004; Neufeld et al.,
1999). In a rat model of IOP-induced ischemia, systemic
treatment with antagonists of the NMDA and non-NMDA
subtypes of glutamate receptors prevents RGC death, and
a similar neuroprotective eﬀect is produced by systemic
treatment with L-NAME (Nucci et al., 2005).
L-NAME (NG-nitro-L-arginine-methyl-ester) is a com-
petitive inhibitor of the enzyme NOS. So, in this study,
the neuroprotective eﬀects of L-NAME on retinas subjected
to chronically elevated IOP were conﬁrmed by determining
numbers of RGCs, not the level of NOS expression. We
observed that L-NAME caused a reduction in the RGC
loss induced by chronically elevated IOP; however, this
eﬀect was not statistically signiﬁcant, when assessed by a
two-tailed t-test (P = .0618). This result may reﬂect a lim-
ited role for NO in RGC loss in the glaucoma model, or it
may be an artifact (a type-II error) of the relatively small
sample size (n = 6 rats per group). L-NAME could aﬀect
nNOS expression in the retina, as well as iNOS expression
in the optic nerve head, but an increase in iNOS was not
observed in our animal glaucoma model.
In our study, L-NAME did not decrease IOP. This ﬁnd-
ing conﬂicts with those of some other studies concerning L-
NAME and IOP. For example, systemic (1–100 mg/kg)
and topical (0.5% or 1%) administration of L-NAME was
reported to prevent IOP increase in an animal model of
glaucoma (Giuﬀrida, Bucolo, & Drago, 2003; Taniguchi
et al., 1998). Furthermore, Kiel, Reitsamer, Walker, and
Kiel (2001) reported that systemic NOS inhibition induces
ciliary vasoconstriction and decreases production of aque-
ous humor. NO reactivity is enriched at major sites of out-
ﬂow resistance, including the trabecular meshwork,
Schlemm’s canal, and ciliary muscles, and NOS type 3 is
the principle NOS isoenzyme found in these areas (Nathan-
son & McKee, 1995). Some evidence suggests that NO reg-
ulates IOP by inducing relaxation of the ciliary muscle and
trabecular meshwork, thereby decreasing the resistance of
the outﬂow pathway (Ding & Abdel-Latif, 1997; Kotiko-
ski, Vapaatalo, & Oksala, 2003; Wiederholt, Sturm, & Lep-
ple-Wienhues, 1994). The apparent lack of agreement with
our results may arise from our use of a diﬀerent glaucoma
model; for example, Giuﬀrida et al. (2003) used a model in
which outﬂow of the aqueous humor was irreversibly
blocked by injection of a-chymotrypsin. In our glaucoma
rat model, IOP was unaﬀected by L-NAME treatment, pos-
S.H. Park et al. / Vision Research 47 (2007) 2732–2740 2739sibly because L-NAME may aﬀect not only the production
of aqueous humor but also the outﬂow resistance.
In conclusion, the results of this study conﬁrm that ret-
inal levels of nNOS are increased in a glaucoma rat model,
as compared to normal rats. This ﬁnding lends support to
the possibility that excessive NO production may damage
RGCs. The increased expression of nNOS in RGCs may
provide a clue to the somatic events of glaucomatous optic
neuropathy.
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